Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

Optimal sequencing of the first-and second-line target therapies in metastatic renal cell carcinoma: Based on nationally representative data analysis from the Korean National Health Insurance System

13 p | 5 | 2

Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma

12 p | 16 | 2

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry

11 p | 11 | 2

Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma

9 p | 11 | 1

Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: The largest multicenter retrospective analysis of survival and prognostic factors

10 p | 6 | 1

Preoperative cholesterol level as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with cyto-reductive nephrectomy

7 p | 10 | 1

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

4 p | 6 | 1

Everolimus in metastatic renal cell carcinoma after failure of initial anti–VEGF therapy: Final results of a noninterventional study

10 p | 13 | 0

Axitinib, cabozantinib, or everolimus in the treatment of prior sunitinib-treated patients with metastatic renal cell carcinoma: Results of matching-adjusted indirect comparison analyses

12 p | 9 | 0